Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the <scp>FDA</scp> Adverse Event Reporting System ( <scp>FAERS</scp> ) With a Focus on Pericardial Effusions
Our study, the first FAERS-based signal detection study for LDOM, found significant associations between LDOM use and several AEs. In the absence of causal evidence, these correlations warrant more attention regarding safe use of LDOM. Until more safety data are available, we recommend using LDOM at the lowest effective dose (≤5 mg/day).
Authors
- Husam Mohamed Abdel-Qadir (ORCID: https://orcid.org/0000-0002-7105-7931)
- Vincent Piguet (ORCID: https://orcid.org/0000-0001-6079-4517)
- Mary A. Bamimore (ORCID: https://orcid.org/0000-0002-5610-375X)
- Mesbah Talukder (ORCID: https://orcid.org/0000-0003-0691-640X)
- Antonellá Tosti (ORCID: https://orcid.org/0000-0001-5516-4043)
- Aditya Kumar Gupta (ORCID: https://orcid.org/0000-0002-8664-7723)
- Greg Williams (ORCID: https://orcid.org/0000-0003-2765-5173)
Institutions
- University Health Network (CA)
- University of Miami (US)
- University of Toronto (CA)
- Women's College Hospital (CA)
- Mediprobe Research (Canada) (CA)
- BRAC University (BD)
Publication Details
- Journal
- Journal of Cosmetic Dermatology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1111/jocd.16574
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.70